-+ 0.00%
-+ 0.00%
-+ 0.00%

BEYONDSPRING PRESENTS UPDATED EFFICACY RESULTS FROM A PHASE 2 IIT STUDY OF TRIPLE IO COMBO OF PEMBROLIZUMAB PLUS PLINABULIN/DOCETAXEL IN METASTATIC NSCLC AFTER PROGRESSING ON PRIOR IMMUNE CHECKPOINT INHIBITORS AT THE 39TH SITC ANNUAL MEETING

Reuters·11/11/2024 13:00:03

Please log in to view news